TY  - JOUR
AU  - Pires, Ana Salomé
AU  - Bollini, Sveva
AU  - Botelho, Maria Filomena
AU  - Lang-Olip, Ingrid
AU  - Ponsaerts, Peter
AU  - Balbi, Carolina
AU  - Lange-Consiglio, Anna
AU  - Fénelon, Mathilde
AU  - Mojsilović, Slavko
AU  - Berishvili, Ekaterine
AU  - Cremonesi, Fausto
AU  - Gazouli, Maria
AU  - Bugarski, Diana
AU  - Gellhaus, Alexandra
AU  - Kerdjoudj, Halima
AU  - Schoeberlein, Andreina
PY  - 2023
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1297
AB  - The last 18 years have brought an increasing interest in the therapeutic use of perinatal derivatives (PnD). Preclinical studies used to assess the potential of PnD therapy include a broad range of study designs. The COST SPRINT Action (CA17116) aims to provide systematic and comprehensive reviews of preclinical studies for the understanding of the therapeutic potential and mechanisms of PnD in diseases and injuries that benefit from PnD therapy. Here we describe the publication search and data mining, extraction, and synthesis strategies employed to collect and prepare the published data selected for meta-analyses and reviews of the efficacy of PnD therapies for different diseases and injuries. A coordinated effort was made to prepare the data suitable to make statements for the treatment efficacy of the different types of PnD, routes, time points, and frequencies of administration, and the dosage based on clinically relevant effects resulting in clear increase, recovery or amelioration of the specific tissue or organ function. According to recently proposed guidelines, the harmonization of the nomenclature of PnD types will allow for the assessment of the most efficient treatments in various disease models. Experts within the COST SPRINT Action (CA17116), together with external collaborators, are doing the meta-analyses and reviews using the data prepared with the strategies presented here in the relevant disease or research fields. Our final aim is to provide standards to assess the safety and clinical benefit of PnD and to minimize redundancy in the use of animal models following the 3R principles for animal experimentation.
PB  - Multidisciplinary Digital Publishing Institute (MDPI)
T2  - Methods and Protocols
T1  - Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives
IS  - 3
SP  - 45
VL  - 6
DO  - 10.3390/mps6030045
ER  - 

@article{
author = "Pires, Ana Salomé and Bollini, Sveva and Botelho, Maria Filomena and Lang-Olip, Ingrid and Ponsaerts, Peter and Balbi, Carolina and Lange-Consiglio, Anna and Fénelon, Mathilde and Mojsilović, Slavko and Berishvili, Ekaterine and Cremonesi, Fausto and Gazouli, Maria and Bugarski, Diana and Gellhaus, Alexandra and Kerdjoudj, Halima and Schoeberlein, Andreina",
year = "2023",
abstract = "The last 18 years have brought an increasing interest in the therapeutic use of perinatal derivatives (PnD). Preclinical studies used to assess the potential of PnD therapy include a broad range of study designs. The COST SPRINT Action (CA17116) aims to provide systematic and comprehensive reviews of preclinical studies for the understanding of the therapeutic potential and mechanisms of PnD in diseases and injuries that benefit from PnD therapy. Here we describe the publication search and data mining, extraction, and synthesis strategies employed to collect and prepare the published data selected for meta-analyses and reviews of the efficacy of PnD therapies for different diseases and injuries. A coordinated effort was made to prepare the data suitable to make statements for the treatment efficacy of the different types of PnD, routes, time points, and frequencies of administration, and the dosage based on clinically relevant effects resulting in clear increase, recovery or amelioration of the specific tissue or organ function. According to recently proposed guidelines, the harmonization of the nomenclature of PnD types will allow for the assessment of the most efficient treatments in various disease models. Experts within the COST SPRINT Action (CA17116), together with external collaborators, are doing the meta-analyses and reviews using the data prepared with the strategies presented here in the relevant disease or research fields. Our final aim is to provide standards to assess the safety and clinical benefit of PnD and to minimize redundancy in the use of animal models following the 3R principles for animal experimentation.",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
journal = "Methods and Protocols",
title = "Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives",
number = "3",
pages = "45",
volume = "6",
doi = "10.3390/mps6030045"
}

Pires, A. S., Bollini, S., Botelho, M. F., Lang-Olip, I., Ponsaerts, P., Balbi, C., Lange-Consiglio, A., Fénelon, M., Mojsilović, S., Berishvili, E., Cremonesi, F., Gazouli, M., Bugarski, D., Gellhaus, A., Kerdjoudj, H.,& Schoeberlein, A.. (2023). Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives. in Methods and Protocols
Multidisciplinary Digital Publishing Institute (MDPI)., 6(3), 45.
https://doi.org/10.3390/mps6030045

Pires AS, Bollini S, Botelho MF, Lang-Olip I, Ponsaerts P, Balbi C, Lange-Consiglio A, Fénelon M, Mojsilović S, Berishvili E, Cremonesi F, Gazouli M, Bugarski D, Gellhaus A, Kerdjoudj H, Schoeberlein A. Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives. in Methods and Protocols. 2023;6(3):45.
doi:10.3390/mps6030045 .

Pires, Ana Salomé, Bollini, Sveva, Botelho, Maria Filomena, Lang-Olip, Ingrid, Ponsaerts, Peter, Balbi, Carolina, Lange-Consiglio, Anna, Fénelon, Mathilde, Mojsilović, Slavko, Berishvili, Ekaterine, Cremonesi, Fausto, Gazouli, Maria, Bugarski, Diana, Gellhaus, Alexandra, Kerdjoudj, Halima, Schoeberlein, Andreina, "Guidelines to Analyze Preclinical Studies Using Perinatal Derivatives" in Methods and Protocols, 6, no. 3 (2023):45,
https://doi.org/10.3390/mps6030045 . .

TY  - JOUR
AU  - Pichlsberger, Melanie
AU  - Jerman, Urška Dragin
AU  - Obradović, Hristina
AU  - Tratnjek, Larisa
AU  - Macedo, Ana Sofia
AU  - Mendes, Francisca
AU  - Fonte, Pedro
AU  - Hoegler, Anja
AU  - Sundl, Monika
AU  - Fuchs, Julia
AU  - Schoeberlein, Andreina
AU  - Kreft, Mateja Erdani
AU  - Mojsilović, Slavko
AU  - Lang-Olip, Ingrid
PY  - 2021
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1177
AB  - Knowledge of the beneficial effects of perinatal derivatives (PnD) in wound healing goes back to the early 1900s when the human fetal amniotic membrane served as a biological dressing to treat burns and skin ulcerations. Since the twenty-first century, isolated cells from perinatal tissues and their secretomes have gained increasing scientific interest, as they can be obtained non-invasively, have anti-inflammatory, anti-cancer, and anti-fibrotic characteristics, and are immunologically tolerated in vivo. Many studies that apply PnD in pre-clinical cutaneous wound healing models show large variations in the choice of the animal species (e.g., large animals, rodents), the choice of diabetic or non-diabetic animals, the type of injury (full-thickness wounds, burns, radiation-induced wounds, skin flaps), the source and type of PnD (placenta, umbilical cord, fetal membranes, cells, secretomes, tissue extracts), the method of administration (topical application, intradermal/subcutaneous injection, intravenous or intraperitoneal injection, subcutaneous implantation), and the type of delivery systems (e.g., hydrogels, synthetic or natural biomaterials as carriers for transplanted cells, extracts or secretomes). This review provides a comprehensive and integrative overview of the application of PnD in wound healing to assess its efficacy in preclinical animal models. We highlight the advantages and limitations of the most commonly used animal models and evaluate the impact of the type of PnD, the route of administration, and the dose of cells/secretome application in correlation with the wound healing outcome. This review is a collaborative effort from the COST SPRINT Action (CA17116), which broadly aims at approaching consensus for different aspects of PnD research, such as providing inputs for future standards for the preclinical application of PnD in wound healing.
PB  - Frontiers Media S.A.
T2  - Frontiers in Bioengineering and Biotechnology
T1  - Systematic Review of the Application of Perinatal Derivatives in Animal Models on Cutaneous Wound Healing
SP  - 742858
VL  - 9
DO  - 10.3389/fbioe.2021.742858
ER  - 

@article{
author = "Pichlsberger, Melanie and Jerman, Urška Dragin and Obradović, Hristina and Tratnjek, Larisa and Macedo, Ana Sofia and Mendes, Francisca and Fonte, Pedro and Hoegler, Anja and Sundl, Monika and Fuchs, Julia and Schoeberlein, Andreina and Kreft, Mateja Erdani and Mojsilović, Slavko and Lang-Olip, Ingrid",
year = "2021",
abstract = "Knowledge of the beneficial effects of perinatal derivatives (PnD) in wound healing goes back to the early 1900s when the human fetal amniotic membrane served as a biological dressing to treat burns and skin ulcerations. Since the twenty-first century, isolated cells from perinatal tissues and their secretomes have gained increasing scientific interest, as they can be obtained non-invasively, have anti-inflammatory, anti-cancer, and anti-fibrotic characteristics, and are immunologically tolerated in vivo. Many studies that apply PnD in pre-clinical cutaneous wound healing models show large variations in the choice of the animal species (e.g., large animals, rodents), the choice of diabetic or non-diabetic animals, the type of injury (full-thickness wounds, burns, radiation-induced wounds, skin flaps), the source and type of PnD (placenta, umbilical cord, fetal membranes, cells, secretomes, tissue extracts), the method of administration (topical application, intradermal/subcutaneous injection, intravenous or intraperitoneal injection, subcutaneous implantation), and the type of delivery systems (e.g., hydrogels, synthetic or natural biomaterials as carriers for transplanted cells, extracts or secretomes). This review provides a comprehensive and integrative overview of the application of PnD in wound healing to assess its efficacy in preclinical animal models. We highlight the advantages and limitations of the most commonly used animal models and evaluate the impact of the type of PnD, the route of administration, and the dose of cells/secretome application in correlation with the wound healing outcome. This review is a collaborative effort from the COST SPRINT Action (CA17116), which broadly aims at approaching consensus for different aspects of PnD research, such as providing inputs for future standards for the preclinical application of PnD in wound healing.",
publisher = "Frontiers Media S.A.",
journal = "Frontiers in Bioengineering and Biotechnology",
title = "Systematic Review of the Application of Perinatal Derivatives in Animal Models on Cutaneous Wound Healing",
pages = "742858",
volume = "9",
doi = "10.3389/fbioe.2021.742858"
}

Pichlsberger, M., Jerman, U. D., Obradović, H., Tratnjek, L., Macedo, A. S., Mendes, F., Fonte, P., Hoegler, A., Sundl, M., Fuchs, J., Schoeberlein, A., Kreft, M. E., Mojsilović, S.,& Lang-Olip, I.. (2021). Systematic Review of the Application of Perinatal Derivatives in Animal Models on Cutaneous Wound Healing. in Frontiers in Bioengineering and Biotechnology
Frontiers Media S.A.., 9, 742858.
https://doi.org/10.3389/fbioe.2021.742858

Pichlsberger M, Jerman UD, Obradović H, Tratnjek L, Macedo AS, Mendes F, Fonte P, Hoegler A, Sundl M, Fuchs J, Schoeberlein A, Kreft ME, Mojsilović S, Lang-Olip I. Systematic Review of the Application of Perinatal Derivatives in Animal Models on Cutaneous Wound Healing. in Frontiers in Bioengineering and Biotechnology. 2021;9:742858.
doi:10.3389/fbioe.2021.742858 .

Pichlsberger, Melanie, Jerman, Urška Dragin, Obradović, Hristina, Tratnjek, Larisa, Macedo, Ana Sofia, Mendes, Francisca, Fonte, Pedro, Hoegler, Anja, Sundl, Monika, Fuchs, Julia, Schoeberlein, Andreina, Kreft, Mateja Erdani, Mojsilović, Slavko, Lang-Olip, Ingrid, "Systematic Review of the Application of Perinatal Derivatives in Animal Models on Cutaneous Wound Healing" in Frontiers in Bioengineering and Biotechnology, 9 (2021):742858,
https://doi.org/10.3389/fbioe.2021.742858 . .